BBW
LGND icon

Blue Barn Wealth’s Ligand Pharmaceuticals LGND Stock Holding History

Blue Barn Wealth’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,423
Closed -$252K – 105
2025
Q3 		$252K Buy
+1,423
New +$212K 0.11% 127

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Blue Barn Wealth's LGND Position: Q4 2025 in Review

Blue Barn Wealth sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 1,423 shares — an estimated $252K sold.

Blue Barn Wealth first reported a position in LGND in Q3 2025 and held it in 1 quarter. The position peaked at $252K in Q3 2025. 349 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • Blue Barn Wealth reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Blue Barn Wealth sold 1,423 Ligand Pharmaceuticals shares in Q4 2025, an estimated $252K.
  • Blue Barn Wealth first reported a position in Ligand Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Blue Barn Wealth's Ligand Pharmaceuticals position peaked at $252K in Q3 2025.
  • 349 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on Blue Barn Wealth's 13F filing for Q4 2025, filed 10 Feb 2026.